iconLogo
Published:2025/11/7 20:27:05

AIで乳がん試験を爆速化! IT企業に大チャンス✨

超要約: AIで乳がん臨床試験(りんしょうしけん)を効率化(こうりつか)!IT企業が参入(さんにゅう)して、ビジネスチャンスを掴もう!

✨ ギャル的キラキラポイント ✨

● AIがスクリーニングを爆速化!時間短縮で、みんなハッピー🫶 ● 高精度(こうせいど)なAIで、見落としも減るかも!安心だね💕 ● IT企業が医療分野(いりょうぶんや)で大活躍できるチャンス到来!未来が楽しみ🌟


続きは「らくらく論文」アプリで

AI-assisted workflow enables rapid, high-fidelity breast cancer clinical trial eligibility prescreening

Jacob T. Rosenthal / Emma Hahesy / Sulov Chalise / Menglei Zhu / Mert R. Sabuncu / Lior Z. Braunstein / Anyi Li

Clinical trials play an important role in cancer care and research, yet participation rates remain low. We developed MSK-MATCH (Memorial Sloan Kettering Multi-Agent Trial Coordination Hub), an AI system for automated eligibility screening from clinical text. MSK-MATCH integrates a large language model with a curated oncology trial knowledge base and retrieval-augmented architecture providing explanations for all AI predictions grounded in source text. In a retrospective dataset of 88,518 clinical documents from 731 patients across six breast cancer trials, MSK-MATCH automatically resolved 61.9% of cases and triaged 38.1% for human review. This AI-assisted workflow achieved 98.6% accuracy, 98.4% sensitivity, and 98.7% specificity for patient-level eligibility classification, matching or exceeding performance of the human-only and AI-only comparisons. For the triaged cases requiring manual review, prepopulating eligibility screens with AI-generated explanations reduced screening time from 20 minutes to 43 seconds at an average cost of $0.96 per patient-trial pair.

cs / cs.LG